Etoposide in prostate cancer

Jeffrey M. Kamradt, Kenneth Pienta

Research output: Contribution to journalArticle

Abstract

Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year. No single chemotherapeutic agent or regimen has been demonstrated to provide a survival advantage in this disease. Etoposide as a single agent, both in iv. and oral formulations has not proven to be effective. In the 1990s, however, etoposide has been combined with several agents to create novel treatment regimens for patients with hormone refractory disease. Several of these regimens, all involving oral etoposide, have demonstrated promising results in Phase II trials and early results suggest that they may increase survival for hormone refractory patients, although this remains to be tested in a Phase III trial setting. 2000

Original languageEnglish (US)
Pages (from-to)271-275
Number of pages5
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number2
StatePublished - 2000
Externally publishedYes

Fingerprint

Etoposide
Prostatic Neoplasms
Hormones
Survival
Therapeutics

Keywords

  • Estrannistine
  • Etoposide
  • Hormone refractory prostate cancer
  • Nuclear matrix
  • Oral chemotherapy
  • Prostate cancer

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Etoposide in prostate cancer. / Kamradt, Jeffrey M.; Pienta, Kenneth.

In: Expert Opinion on Pharmacotherapy, Vol. 1, No. 2, 2000, p. 271-275.

Research output: Contribution to journalArticle

Kamradt, JM & Pienta, K 2000, 'Etoposide in prostate cancer', Expert Opinion on Pharmacotherapy, vol. 1, no. 2, pp. 271-275.
Kamradt, Jeffrey M. ; Pienta, Kenneth. / Etoposide in prostate cancer. In: Expert Opinion on Pharmacotherapy. 2000 ; Vol. 1, No. 2. pp. 271-275.
@article{80b532d0c31d4efaa1754d378a4d4c19,
title = "Etoposide in prostate cancer",
abstract = "Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year. No single chemotherapeutic agent or regimen has been demonstrated to provide a survival advantage in this disease. Etoposide as a single agent, both in iv. and oral formulations has not proven to be effective. In the 1990s, however, etoposide has been combined with several agents to create novel treatment regimens for patients with hormone refractory disease. Several of these regimens, all involving oral etoposide, have demonstrated promising results in Phase II trials and early results suggest that they may increase survival for hormone refractory patients, although this remains to be tested in a Phase III trial setting. 2000",
keywords = "Estrannistine, Etoposide, Hormone refractory prostate cancer, Nuclear matrix, Oral chemotherapy, Prostate cancer",
author = "Kamradt, {Jeffrey M.} and Kenneth Pienta",
year = "2000",
language = "English (US)",
volume = "1",
pages = "271--275",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Etoposide in prostate cancer

AU - Kamradt, Jeffrey M.

AU - Pienta, Kenneth

PY - 2000

Y1 - 2000

N2 - Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year. No single chemotherapeutic agent or regimen has been demonstrated to provide a survival advantage in this disease. Etoposide as a single agent, both in iv. and oral formulations has not proven to be effective. In the 1990s, however, etoposide has been combined with several agents to create novel treatment regimens for patients with hormone refractory disease. Several of these regimens, all involving oral etoposide, have demonstrated promising results in Phase II trials and early results suggest that they may increase survival for hormone refractory patients, although this remains to be tested in a Phase III trial setting. 2000

AB - Hormone refractory prostate cancer is a disease that kills approximately 39,000 people per year. No single chemotherapeutic agent or regimen has been demonstrated to provide a survival advantage in this disease. Etoposide as a single agent, both in iv. and oral formulations has not proven to be effective. In the 1990s, however, etoposide has been combined with several agents to create novel treatment regimens for patients with hormone refractory disease. Several of these regimens, all involving oral etoposide, have demonstrated promising results in Phase II trials and early results suggest that they may increase survival for hormone refractory patients, although this remains to be tested in a Phase III trial setting. 2000

KW - Estrannistine

KW - Etoposide

KW - Hormone refractory prostate cancer

KW - Nuclear matrix

KW - Oral chemotherapy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0033764889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033764889&partnerID=8YFLogxK

M3 - Article

C2 - 11249548

AN - SCOPUS:0033764889

VL - 1

SP - 271

EP - 275

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -